HEALTH PROFESSIONAL · SOURCE READING

Supportive care and close monitoring of infants on sirolimus

Source: Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 17, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Intermediate Tumors (Locally Aggressive) / Kaposiform Hemangioendothelioma and Tufted Angioma / Treatment of kaposiform hemangioendothelioma and tufted angioma / Treatment of complicated kaposiform hemangioendothelioma and tufted angioma

A case report described two children with kaposiform hemangioendotheliomas and Kasabach-Merritt syndrome who died of pulmonary infections after treatment with sirolimus.[38] Another child who received sirolimus and prednisolone developed Pneumocystis jirovecii pneumonia.[39] P. jirovecii pneumonia prophylaxis and close monitoring of patients on sirolimus (especially infants) is encouraged.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice